Cardiosense
Cardiosense is developing innovative wearable sensors and advanced machine learning algorithms to improve early detection and management of heart disease. The company collaborates with leading academic institutions to advance cardiac monitoring and disease management solutions.
Cardiosense is a medical device company focused on heart failure management, offering the CardioTag™ — the world's first FDA-cleared noninvasive device that measures Pulmonary Capillary Wedge Pressure (PCWP) at point-of-care. Their platform combines wearable sensor technology with AI-driven signal processing to deliver real-time hemodynamic insights for clinicians across emergency, inpatient, and outpatient settings. Cardiosense's tools are designed to enable earlier intervention, reduce hospitalizations, and improve long-term outcomes for heart failure patients.
Cardiosense's CardioTag Device Gets FDA 510(k) Clearance for Advanced Cardiac Function Monitoring
Jul 30, 2025
Cardiosense Presents New Analysis of the SEISMIC-HF I Study Validating its AI Algorithm for Noninvasive PCWP Assessment at the American Heart Association's 2025 Scientific Sessions
Nov 6, 2025
Cardiosense names Eric Meizlish as CEO
Sep 24, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Cardiosense.
Cardiosense scores FDA clearance for wearable sensor that monitors heart function
Jul 30, 2025